Q-omics provides the consensus-scored HILPDA profile across patient tissues and cancer cell-line models. HILPDA expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, HILPDA is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, HILPDA RNA expression shows 18,276 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, KIRC, and ACC as cancer lineages where HILPDA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HILPDA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HILPDA survival associations across molecular data types. HILPDA RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HILPDA RNA expression–survival associations across cancer types. High HILPDA expression shows unfavorable associations in KICH, LIHC, HNSC, ACC, MESO and KIRP. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for HILPDA RNA expression.
This table summarizes HILPDA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HILPDA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HILPDA shows higher tumor expression in KIRC, COAD, LUAD, HNSC, BLCA and LIHC. The KIRC box plot shows higher HILPDA RNA expression in tumor versus normal tissue (log2 FC = +4.779, t-test p < 0.001).
This table shows molecular features associated with HILPDA in patient tissues and cancer cell lines. In patient samples, HILPDA shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, HILPDA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
